1	Should	women	have	lower	blood	pressure	targets
---	--------	-------	------	-------	-------	----------	---------

than men? Sex differences in blood pressure and

cardiovascular disease in the UK Biobank

4	
5	Rebecca K Kelly ^{1,2} , MD, PhD, Katie Harris ¹ , PhD, Cheryl Carcel ^{1,3} , MD, PhD, Paul
6	Muntner, PhD ¹ , Mark Woodward ^{1,5} , PhD
7	
8	1. The George Institute for Global Health, University of New South Wales, Sydney,
9	New South Wales, Australia
10	2. School of Medicine, College of Health and Medicine, University of Tasmania,
11	Hobart, Tasmania, Australia
12	3. Department of Neurology, Royal Prince Alfred Hospital, Sydney, New South
13	Wales, Australia
14	4. Department of Epidemiology, University of Alabama at Birmingham, Birmingham,
15	AL, USA
16	5. The George Institute for Global Health, Imperial College London, London, United
17	Kingdom
18	
19	Short title: Should women have lower blood pressure targets?
20	
21	Corresponding author: Dr Rebecca K Kelly, The George Institute for Global Health,
22	Three International Towers, Level 18/300 Barangaroo Avenue, Barangaroo NSW

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- 23 2000, Australia. Telephone: +61 2 8052 4300. Fax: +61 2 8052 4301. E-mail:
- 24 <u>RKelly@georgeinstitute.org.au</u>.
- 25
- 26 **Total word count:** 6,434 (including Title Page, Abstract, Text, References, Tables
- 27 and Figures Legends)

28 Abstract

Background: Recent studies show that the risk of cardiovascular disease (CVD) increases from a lower nadir of systolic blood pressure (SBP) in women than men, and increases thereafter at a greater rate. This has led to a suggestion that sex-based SBP thresholds are required. We aimed to investigate sex differences in the associations of SBP and incident atherosclerotic CVD in a large prospective cohort.

Methods: 420,649 UK Biobank participants with no prior history of CVD were included. Age-adjusted sex-specific risks, relative risks (RRs) and risk differences (RDs) relating SBP to CVD were estimated using Poisson and Cox regression.

37 **Results:** Over 13.2 years of follow-up there were 28,628 CVD events. CVD risks 38 across BP levels showed a "J-shape", and were higher in men than women at all BP 39 levels. The lowest risks were at SBP 100-<105 mmHg (events per 10,000 person-40 years [95%CI]: 15.6 [11.8-23.1]) and 110-<115 (47.2 [41.8-53.0]) among women and 41 men, respectively. Compared with SBP 100-<110, sex-specific RRs at above 120 42 were higher in women than men, but RDs were higher in men than women at all levels 43 of SBP. Furthermore, compared to men at 100-<110 (i.e. the men with least risk), risks in women were lower at all levels of SBP below 170. 44

45 Conclusions CVD risk is lowest for women at a slightly lower SBP than men and RRs
46 for CVD increase with SBP at a slightly steeper rate in women. However, both risks
47 and RDs in women are never greater than in men. This evidence suggests that women
48 should not have lower BP thresholds.

49 **Keywords:** sex differences, hypertension, coronary heart disease, stroke

50 Clinical Perspective

51 What is New?

- While risks are higher at lower BP levels in women than men when both sexes
- 53 are considered independently, consideration of the risks and sex-combined
- 54 analyses do not support treating women at lower BP levels than men.
- 55 What are the Clinical Implications?
- In line with 2017 ACC/AHA guideline, antihypertensive treatment thresholds
 should be based on absolute risk calculated from sex-specific algorithms, rather
 than BP level in isolation.
- Both risks and relative risks must be taken into account to understand sex differences in the relationship of BP-CVD and whether these differences are
 clinically meaningful.

Non-standard Abbreviations and Acronyms 62

- ACC = American College of Cardiology 63
- AHA = American Heart Association 64
- 65 LRT = likelihood ratio test
- NHANES = National Health and Nutrition Examination Survey 66
- **OPCS = Operating Procedure Codes Supplement** 67
- 68 RD = risk difference

69 Introduction

Hypertension guidelines do not currently provide sex-based recommendations for initiating blood pressure (BP)-lowering therapy, citing limited evidence.¹⁻³ However, a recent scientific statement from the European Society of Cardiology acknowledges that sex-specific thresholds for hypertension may be reasonable because the risk for cardiovascular disease (CVD) associated with higher BP starts at lower levels in women than men.³

76 Several observational studies have found that the relationship between BP and CVD differs by sex.⁴⁻⁸ These studies found higher relative risks (RRs) of CVD, compared to 77 a low BP reference level, for women than men, as well as a lower nadir in the "J-78 79 shaped" association between BP and CVD in women than men.^{4,8} This has raised the question as to whether women should routinely be treated with antihypertensive 80 medication at lower BP levels than men.^{3,9} However, none of these studies has 81 82 reported this in the context of sex-specific risk differences (RDs), rather than RRs, or compared the RRs for women and men against a common reference group. In 83 84 addition, several previous meta-analyses, have not found substantial sex difference in RRs for the relationship of BP with CVD events,¹⁰⁻¹² or in the efficacy of BP lowering 85 treatments.¹³ 86

To address these uncertainties, we sought to use data from a large cohort of data, with more CVD events than has been previously analyzed, enabling precise measures within smaller ranges of BP than have previously been used. Furthermore, we

- 90 examine whether the sex-differential association between BP and CVD differs by age,
- 91 and the effect menopause has on the BP-CVD relationship in women.¹⁴

92 Methods

93 Subjects and study design

The UK Biobank is a prospective cohort study that includes approximately 500,000 94 men and women recruited between 2006 and 2010.^{15,16} Eligible adults aged between 95 40-69 years were invited to visit one of 22 centers for the baseline assessment, where 96 97 detailed information on lifestyle and medical history was collected via a Touchscreen questionnaire and face-to-face interview, and physical measurements and biological 98 99 samples were collected. Participants have been followed up for various health-related 100 outcomes via linking to electronic health records. Further details, including the study 101 protocol and data access permissions, are available online, and recruitment methods are described in detail elsewhere.¹⁶ All individuals provided informed written consent 102 to participate and the study was approved by the National Information Governance 103 Board for Health and Social care and the National Health Service North West 104 105 Multicentre Research Ethics Committee (reference number 21/NW/0157). Bona fide researchers can apply to use the UK Biobank dataset by registering and applying at 106 http://ukbiobank.ac.uk/register-apply/. 107

Participants were excluded from the present study if they withdrew consent (n=961), or had a history of CVD (self-reported or via linked electronic health records) prior to the baseline assessment, n=40,270), or did not have two automated measurements of systolic BP (SBP) and diastolic BP (DBP) at baseline after exclude excluding extreme measurements (n=41,437) (Figure S1).

113 Measurement of blood pressure

SBP and DBP, in millimeters of mercury, were calculated as the mean of two measurements taken at least one minute apart, taken using an Omron HEM-7015IT digital BP monitor (Omron Healthcare). Hypertension was categorized using the American Heart Association (AHA) 2017 guidelines (no hypertension: SBP <130 mmHg and DBP <80 mmHg; and hypertension: SBP ≥130 mmHg or DBP ≥80 mmHg).¹⁷

120 Outcomes

121 The primary outcome was incident atherosclerotic CVD, defined as a primary 122 diagnosis of fatal or non-fatal coronary heart disease (CHD) or stroke. Secondary outcomes were incident CHD and stroke. Participant information on the date and 123 124 cause of hospital admission(s) or death was obtained through linkage to hospital inpatient and death data.¹⁸ The present analyses were censored separately for 125 126 incident CVD outcomes at the date of diagnosis or death, loss to follow-up, or 127 administrative censoring for each country (31st October 2022 for England, 31st August 2022 for Scotland, 31st May 2022 for Wales) whichever occurred first. CHD was 128 129 defined by a primary diagnosis of incident (fatal or non-fatal) CHD (ICD-10 [international classification of diseases, 10th revision] codes [21-I25] or coronary 130 131 revascularization (OPCS-4 [Classification of Interventions and Procedures, 4th revision] codes K49, K50, K75, K40-K46). Stroke was defined by a primary diagnosis 132 133 of incident (fatal or non-fatal) stroke (ICD-10 codes I60-I61, I63-I64).

134 Statistical analyses

Baseline characteristics for the overall population and women and men separately are presented as number (percentage) for categorical variables, or mean (standard deviation) or median (interquartile interval) for continuous variables as appropriate.

Sex-differences in the relationship of BP with CVD outcomes were explored using 138 139 three approaches: (i) sex-specific risks and risk differences, (ii) sex-specific RRs, and 140 (iii) sex-combined RRs. Poisson regression models were used to obtain age-adjusted 141 rates and rate differences of incident CVD events (per 10,000 person-years), by sex and BP group.¹⁹ Cox proportional hazards regression models were used to estimate 142 hazard ratios for CVD.¹⁹ For simplicity and ease of interpretation, Poisson-derived 143 rates and Cox-derived hazards ratios are hereafter referred to as 'risks' and 'relative 144 145 risks' (RRs), respectively. SBP and DBP were modelled using ordinal groups of 5 mm Hg, with reference groups for BP chosen based on previous literature.^{4,8} For sex-146 147 specific analyses, SBP 110-<115 mmHg and DBP 70-<75 mmHg in women and men 148 were taken as the reference groups for each sex taken separately. For sex-combined analyses, men with SBP 100-<115 mmHg and men with DBP 70-<75 mmHg were 149 150 taken as the common reference groups for both sexes. Then the sex-specific BP-CVD 151 association was modelled continuously in increments of 10 mmHg for SBP and 5 mmHg for DBP, for both sexes. Finally, BP was modelled using the 2017 ACC/AHA 152 BP guideline categories.¹⁷ 153

All analyses were adjusted for age at recruitment (years), and multivariable models were additionally adjusted for the Townsend deprivation index (fifths from least to most affluent using national cut-off points, unknown), smoking status (never, former, light smokers [<15 cigarettes/d], medium smokers [15-<30 cigarettes/d], heavy smokers

[≥30 cigarettes/d], smoker of unknown number of cigarettes, unknown), body mass
index (BMI; kg/m², unknown), diabetes (yes, no, unknown), antihypertensive
medication use (yes, no, unknown), lipid-lowering medication use (yes, no, unknown),
total cholesterol (mmol/L), and high-density lipoprotein cholesterol (HDL-C; mmol/L).
Percentages of missing for each covariate were <7%, except for HDL-C (14.0%)
(Table S1).

164 Subgroup analyses

165 To investigate whether sex differences in the associations of BP with CVD differed by age group (<50, 50-<55, 55-<60, and >60 years), we added a three-way interaction 166 167 between sex, age group, and the BP exposure of interest to the models. To assess 168 trend across age groups separately for men and women (P-trend) and in the three-169 way interaction (P-interaction) we used likelihood ratio tests (LRTs). Similarly, 170 subgroup analyses were conducted by menopausal status (pre-menopausal, 171 menopausal) in women, which was defined by self-report and other relevant factors 172 (such as bilateral oophorectomy and use of hormone-replacement therapy).²⁰

173 Sensitivity analyses

We conducted a sensitivity analysis restricting to participants not taking antihypertensive medication at baseline. Also, to assess the potential influence of regression dilution bias ²¹ we calculated sex-specific regression dilution ratios in a subsample of participants with BP measurements taken, on average, 10.6 years apart (n=51,375, 8.2% of the main study sample). RRs were corrected for regression dilution bias by multiplying the regression coefficients by the reciprocal of the regression dilution ratio.

181 We tested the proportional hazards assumption for our Cox models using Schoenfeld 182 residuals, which showed no evidence of violation for exposures and covariates of 183 interest in multivariable models for any outcome.

184 STATA version 18.0 (StataCorp LP, College Station, Texas) was used for data

analyses and R 4.3.3 (R Core Team, Vienna, Austria) was used to create figures.

186 **Results**

187 The baseline characteristics of 420,649 participants (56.0% women) without prior CVD 188 included in the present analyses are shown in **Table 1**. At baseline, a lower proportion 189 of women than men had hypertension, or taking antihypertensive or lipid lowering 190 medication. Women had higher total cholesterol and HDL-C, and lower BMI. Among 191 both women and men, participants with hypertension were older and had higher BMI, and a higher proportion were taking antihypertensive or lipid-lowering medication 192 193 (Table S2). See Tables S3-S4 for baseline characteristics stratified by sex and SBP 194 categories.

195 Sex-specific risks and risk differences

During a mean follow-up of 13.2 years, there were 28,628 (10,331 women), 21,146 (6,774 women) and 8,321 (3,816 women) cases of incident CVD, CHD and stroke, respectively. Age-adjusted risks of incident CVD showed a "J-shaped" pattern and were higher among men in all categories of SBP and DBP (**Figure 1**). Risks of incident CVD were lowest at SBP 100-<105 mmHg for women (events per 10,000 personyears [95% CI], 15.6 [11.8-19.4]) and 110-<115 mmHg for men (47.2 [41.4-53.0]). Risks of incident CVD were lowest at DBP 60-<65 mmHg for women (22.7 [19.7-25.8])

and 65-<70 mmHg for men (63.3 [58.4-68.1]). Compared with SBP 100-<115 mmHg
and DBP 70-<75 mmHg, sex-specific risk differences at higher levels of BP were larger
among men than women (Table S5). We found similar patterns for CHD and stroke
(Figures S2-S3 and Tables S6-S7).

207 Sex-specific relative risks

208 As would be expected from the risks, for SBP, there was an approximately "J-shaped" 209 relationship for RRs of incident CVD for both sexes, which was roughly log-linear from 210 nadirs of approximately 105 mmHg in women and 115 mmHg in men. Similarly, for 211 DBP, with roughly log-linear increases from nadirs of approximately 65 mmHg in 212 women and 75 mmHg in men (Figure 2). Sex-specific RRs for incident CVD, relative to 110-<115 mmHg for SBP and 70-<75 mmHg for DBP, were lowest at SBP 100-213 214 <105 mmHg (RR [95%CI], 0.76 [0.58-0.99]) and DBP 60-<65 mmHg (0.84 [0.72-0.97]) 215 among women, and lowest at SBP 110-<115 (reference category) and DBP 65-<70 216 mmHg (0.98 [0.90-1.08]) for men, although CIs overlapped between adjacent BP 217 groups. The association between higher SBP and increased RR was steeper among 218 women compared with men. The patterns of sex differences in the associations of BP 219 categories in relation to incident CHD and stroke were broadly similar, but with 220 expected wider CIs (Figures S4-S5). The association between hypertension and CVD 221 was stronger in women (RR hypertension vs no hypertension [95%CI], 1.62 [1.54-222 1.70]) than men (1.45 [1.39-1.52]) (Table S8). Stronger RRs for the associations 223 between continuous BP and CVD were present among women than men. Equivalent, broadly similar, values for multivariable-adjusted RRs for the sex-specific associations 224 of BP with all CVD outcomes are shown in Tables S8-S10. 225

226 Sex-combined relative risks

227 When comparing both women and men to the same reference group, men with SBP 228 110-<115 mmHg (that is, men who had the lowest CVD risk), RRs of incident CVD in 229 women were never higher than unity up to the 170<175 mmHg group and peaked at 230 >180 mmHg when the RR was 1.32 (1.13, 1.53) (Figure 3). So, it is only women with 231 SBP above 170 mmHg that had greater CVD risk than any man, in terms of risk according to SBP level. For DBP level, no category of women had higher risks than 232 the lowest risk group for men of 70-<75 mmHg. Similar patterns were observed for 233 234 CHD and stroke (Figures S6-S7). See Tables S11-S13 for age-adjusted and 235 multivariable-adjusted sex-combined RRs for all CVD outcomes.

236 Subgroup analyses

The patterns of BP-CVD relationships were much the same in subgroup analyses by age (**Figure 4**, Table S14) and by menopause status in women (Table S15). RRs were greater for the associations between BP and incident CVD among younger age groups for both sexes and for pre-menopausal women compared with menopausal women, presumably due to the increasing risk with age.

242 Sensitivity analyses

When excluding participants taking antihypertensive medication at baseline, the directions of association remained similar, although the magnitude of RRs for CVD generally became stronger (Table S16).

Among 51,375 participants with baseline and follow-up BP measurements, regression dilution ratios for SBP and DBP were estimated to be 0.624 and 0.536, respectively, for women and 0.551 and 0.455, respectively, for men (Figure S8-S9). Baseline

characteristics were similar between participants with baseline and follow-up BP measurements and participants in the main study sample (Table S17). After correction for regression dilution, the sex-specific age-adjusted RRs by SBP and DBP levels for women moved slightly closer to those for men (Figure S10).

253 **Discussion**

254 This large study assessed sex-differences in the associations of BP with CVD, as well as CHD and stroke subtypes. CVD risks were higher among men than women at all 255 levels of BP. Whilst there was a clear indication of a log-linear association starting 256 257 substantially lower than current AHA treatment thresholds of SBP >130 mmHg and 258 DBP >80 mmHg for both sexes. There was a "J-shaped" pattern relating increasing BP to CVD outcomes in both sexes, with a lower nadir in women (SBP 100-<105 259 mmHq and DBP 60-<65 mmHq) than men (SBP 110->115 mmHg and DBP mmHg). 260 261 RRs comparing to the reference groups of SBP 110-<115 or DBP 70-<75 were mostly 262 higher for women than for men when the sexes were analyzed totally separately, but RDs showed the opposite relationship (Figure 5). Furthermore, when a common 263 reference group of men with SBP at 110-115 mmHg or men at DBP 70-<75 mmHg 264 265 was used, when analyzing the sexes together, the RRs for women were lower than for men at all BP levels, whilst the risk of CVD in women only exceeded that of men at 266 their lowest level of risk at high levels of BP. 267

There is established evidence that exceeding the existing thresholds for normal BP (SBP > 120 mmHg or DBP >80 mmHg) is associated with an elevated risk of CVD in both sexes.²²⁻²⁴ However, few studies have explored associations of BP levels below these thresholds with CVD risks, or considered BP categories as narrow as in this

272 study.^{4,8,25} A recent study of 53,289 participants in the National Health and Nutrition 273 Examination Survey (NHANES) found the risk of CVD mortality was lowest at SBP 100-<110 mmHg in women and 110-<120 mmHg in men.⁸ Another study of 27,452 274 275 participants in four community-based cohorts found risks of CVD events were lowest at SBP <100 mmHg in women and <130 mmHg in men.⁴ Other studies have 276 277 considered CHD and stroke subtypes and, as in the current study, similar patterns 278 were reported to those with CVD ^{4,6}. In this study there were higher risks present at 279 around SBP <100 mmHg and DBP <60 mmHg, compared to slightly higher BP levels, 280 for both sexes. This appeared to be more pronounced for SBP among men, as well 281 as among women who were menopausal or ≥55 years of age in subgroup analyses. Investigators analyzing NHANES data identified the same pattern for SBP and CVD 282 283 mortality for both men and women.⁸ One explanation is that lower SBP is associated with higher mortality among patients with heart failure 26 and older adults (\geq 80) with 284 285 frailty,²⁷ although our study excluded those with pre-existing CVD and was a 286 predominantly middle-aged cohort.

287 Prior epidemiological studies suggest that the strength of associations between BP and CVD varies by sex.^{4,5,7,8,28,29} Meta-analyses of observational studies have found 288 that RRs for the association of BP with CVD events ¹² and mortality ^{11,30} are stronger 289 290 in women than men, although all studies concluded that these sex-based differences 291 were not substantial. The most recent meta-analysis of 11 observational studies 292 reported that AHA stage 1 hypertension was associated with 50% and 37% higher 293 risks of CVD compared to normal BP in women and men, respectively.¹² Similarly, the 294 present study found that hypertension was associated with a higher excess risk for 295 incident CVD in women (46% higher) than men (32% higher) compared to no

hypertension. However, CVD risks remained higher in men than women forhypertension and across all levels of BP.

298 Studies consistently demonstrate that women have lower mean basal BP than men.^{31,32} The trajectory of BP may differ by sex over time, with women exhibiting faster 299 rise in BP from as early as the third decade of life.³³ The present study examined the 300 301 roles of age and menopausal status, finding higher BP was associated with larger RRs 302 for CVD among women that were pre-menopausal or younger (<55 years). The influence of age on the relationship between BP and CVD was more pronounced 303 304 among women than men, with differences between age, sex and BP observed for all 305 BP metrics.

306 Hormones, as well as anatomic and physiological differences, may explain sexdifferences in optimal BP and BP trajectories over time.⁹ Specifically, estrogen may 307 308 exert benefit effects on the renin-angiotensin-aldosterone system influencing BP 309 homeostasis, and increased plasma renin and sympathetic nerve activity and 310 decreased nitric oxide have been observed in post-menopausal women.³⁴⁻³⁷ 311 Compared with men, women have smaller coronary arteries, smaller aortic root 312 dimensions and lower aortic distensibility with age, as well as higher pulse pressure, 313 which may make women more susceptible to the cardiovascular effects of 314 hypertension.³⁸⁻⁴⁰ Moreover some conditions specific to women, including premature 315 menopause and pregnancy-associated hypertension, may worsen CVD outcomes when coincident with hypertension.⁴¹⁻⁴³ Lastly, emerging evidence suggests that the 316 effect of genetic variants for BP are greater in women than men.⁴⁴ 317

318 Treatment for high BP is typically through antihypertensive drug therapy, although 319 lifestyle changes, including salt reduction, can be expected to assist. In questioning

320 whether women should be treated differently to men it is necessary to consider 321 whether they react to the drugs differently. Individual clinical trials have described sexdifferences in the efficacy, pharmacodynamics and pharmacokinetics, and overall 322 323 women report more adverse effects from antihypertensive medication.(6,7) However, the BP Lowering Treatment Trialists' Collaboration has found that, with 324 antihypertensive drug treatment, BP reductions were similar for women and men in 325 326 every comparison they made, and there was no sex difference in protection against CVD regardless of age or antihypertensive regimen.^{13,30} 327

328 Study strengths and limitations

329 Strengths of this study include the prospective study design and large sample size, 330 which allowed us to examine smaller ranges of BP than previously studied, as well as 331 major CVD subtypes. We also considered the roles of age and menopausal status in 332 more detail than prior studies. There are limitations to our study. BP measurements were taken at a single visit, which may be prone to measurement error.² Indeed, our 333 334 assessment of regression dilution bias in BP using participants with repeat measurements suggests this may have led to an underestimation of reported RRs, 335 particularly among men.⁴⁵ Because of the extensive baseline data available in UK 336 Biobank, we were able to account for potential confounders, including serum total 337 338 cholesterol and HDL-C. However, this study was unable to account for changes in 339 these factors during the follow-up period, and we cannot exclude the effects of unmeasured and residual confounding, particularly in antihypertensive medication 340 341 use. Reverse causation also cannot be ruled out, although we excluded participants 342 with prior CVD at baseline. Finally, the UK Biobank study population is not nationally 343 representative,⁴⁶ being predominantly of white ethnicity and higher than average social

advantage, and so our findings may be prone to selection bias, particularly for risk
estimation, although risk factor associations still appear to be generalizable.⁴⁷ Lastly,
we only studied CVD, whereas normal or optimal BP for other disease outcomes may
differ, and the potential adverse effects at lower BP levels were not examined.

348 **Conclusions**

In this study we have separated the effects of BP levels by risk and RR, which have been confused in past literature (1) and considered narrow increments of BP. Our analyses suggest that the level at which hypertension is defined should not vary by sex. As regards to determining the level at which antihypertensive medication should be initiated to prevent CVD, the definition of hypertension itself is moot, since intervention should depend upon risk, not BP level alone,^{48,49} provided that risk has been estimated using a sex-specific algorithm.

356 Acknowledgements

- 357 This research has been conducted using the UK Biobank Resource under
- 358 application number 74018. We thank all participants, researchers and support staff
- 359 who make the study possible. Bona fide researchers can apply to use the UK
- 360 Biobank dataset by registering and applying at <u>http://ukbiobank.ac.uk/register-apply/</u>.

361 Sources of Funding

- 362 MW is supported by an Australian NHMRC Investigator Grant, Leadership 2
- 363 (APP1174120). CC is supported by an Australian NHMRC Investigator Grant,
- 364 Emerging Leadership 1 (APP2009726).

366 **Disclosures**

- 367 MW has been a recent consultant to Freeline. All Other authors have no
- 368 relationships relevant to the contents of this paper to disclose.

Supplemental Material 369

- Figures S1-S10 370
- 371 Tables S1-S17

372 **References**

- 1. Whelton SP, McEvoy JW, Shaw L, Psaty BM, Lima JAC, Budoff M, Nasir K,
- 374 Szklo M, Blumenthal RS, Blaha MJ. Association of normal systolic blood pressure
- 375 level with cardiovascular disease in the absence of risk factors. JAMA Cardiol.
- 376 2020;5:1011-1018. doi: 10.1001/jamacardio.2020.1731
- 2. Muntner P, Shimbo D, Carey RM, Charleston JB, Gaillard T, Misra S, Myers
- 378 MG, Ogedegbe G, Schwartz JE, Townsend RR, et al. Measurement of blood
- 379 pressure in humans: a scientific statement from the American Heart Association.

380 *Hypertension*. 2019;73:e35-e66. doi: 10.1161/hyp.0000000000000087

Gerdts E, Sudano I, Brouwers S, Borghi C, Bruno RM, Ceconi C, Cornelissen
 V, Diévart F, Ferrini M, Kahan T, et al. Sex differences in arterial hypertension. *Eur Heart J.* 2022;43:4777-4788. doi: 10.1093/eurheartj/ehac470

- Ji H, Niiranen TJ, Rader F, Henglin M, Kim A, Ebinger JE, Claggett B, Merz
 CNB, Cheng S. Sex differences in blood pressure associations with cardiovascular
- 386 outcomes. *Circulation*. 2021;143:761-763. doi: 10.1161/circulationaha.120.049360

5. Boggia J, Thijs L, Hansen TW, Li Y, Kikuya M, Björklund-Bodegård K, Richart

388 T, Ohkubo T, Jeppesen J, Torp-Pedersen C, et al. Ambulatory blood pressure

389 monitoring in 9357 subjects from 11 populations highlights missed opportunities for

390 cardiovascular prevention in women. *Hypertension*. 2011;57:397-405. doi:

391 10.1161/hypertensionaha.110.156828

392 6. Hermida RC, Ayala DE, Mojón A, Fontao MJ, Chayán L, Fernández JR.
393 Differences between men and women in ambulatory blood pressure thresholds for

394	diagnosis of hypertension based on cardiovascular outcomes. Chronobiol Int.
395	2013;30:221-232. doi: 10.3109/07420528.2012.701487
396	7. Kringeland E, Tell GS, Midtbø H, Igland J, Haugsgjerd TR, Gerdts E. Stage 1
397	hypertension, sex, and acute coronary syndromes during midlife: the Hordaland
398	Health Study. Eur J Prev Cardiol. 2022;29:147-154. doi: 10.1093/eurjpc/zwab068
399	8. Elfassy T, German CA, Muntner P, Choi E, Contreras G, Shimbo D, Yang E.
400	Blood pressure and cardiovascular disease mortality among US adults: a sex-
401	stratified analysis, 1999-2019. Hypertension. 2023;80:1452-1462. doi:
402	10.1161/HYPERTENSIONAHA.123.21228
403	9. Chapman N, Ching SM, Konradi AO, Nuyt AM, Khan T, Twumasi-Ankrah B,
404	Cho EJ, Schutte AE, Touyz RM, Steckelings UM, et al. Arterial hypertension in
405	women: state of the art and knowledge gaps. Hypertension. 2023;80:1140-1149. doi:
406	10.1161/hypertensionaha.122.20448
407	10. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance
408	of usual blood pressure to vascular mortality: a meta-analysis of individual data for
409	one million adults in 61 prospective studies. Lancet. 2002;360:1903-1913. doi:
410	10.1016/s0140-6736(02)11911-8
411	11. Lawes CM, Rodgers A, Bennett DA, Parag V, Suh I, Ueshima H, MacMahon
412	S. Blood pressure and cardiovascular disease in the Asia Pacific region. J
413	Hypertens. 2003;21:707-716. doi: 10.1097/00004872-200304000-00013
414	12. Han M, Chen Q, Liu L, Li Q, Ren Y, Zhao Y, Liu D, Zhang D, Liu F, Chen X, et
415	al. Stage 1 hypertension by the 2017 American College of Cardiology/American
416	Heart Association hypertension guidelines and risk of cardiovascular disease events:

- 417 systematic review, meta-analysis, and estimation of population etiologic fraction of
- 418 prospective cohort studies. *J Hypertens*. 2020;38:573-578. doi:
- 419 10.1097/hjh.000000000002321
- 420 13. Bidel Z, Nazarzadeh M, Canoy D, Copland E, Gerdts E, Woodward M, Gupta
- 421 AK, Reid CM, Cushman WC, Wachtell K, et al. Sex-specific effects of blood pressure
- 422 lowering pharmacotherapy for the prevention of cardiovascular disease: an individual
- 423 participant-level data meta-analysis. *Hypertension*. 2023;80:2293-2302. doi:
- 424 10.1161/hypertensionaha.123.21496
- 425 14. Coylewright M, Reckelhoff JF, Ouyang P. Menopause and hypertension: an
- 426 age-old debate. *Hypertension*. 2008;51:952-959. doi:
- 427 10.1161/hypertensionaha.107.105742
- 428 15. Collins R. What makes UK Biobank special? *Lancet*. 2012;379:1173-1174.
- 429 doi: 10.1016/s0140-6736(12)60404-8
- 430 16. Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, Downey P,
- 431 Elliott P, Green J, Landray M, et al. UK biobank: an open access resource for
- identifying the causes of a wide range of complex diseases of middle and old age.
- 433 PLoS Med 2015;12:e1001779. doi: 10.1371/journal.pmed.1001779
- 434 17. Whelton PK, Carey RM, Aronow WS, Casey DE, Jr., Collins KJ, Dennison
- 435 Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW, et al. 2017
- 436 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the
- 437 prevention, detection, evaluation, and management of high blood pressure in adults:
- 438 a report of the American College of Cardiology/American Heart Association Task

439 Force on clinical practice guidelines. *J Am Coll Cardiol*. 2018;71:e127-e248. doi:
440 10.1016/j.jacc.2017.11.006

Kelly RK, Tong TYN, Watling CZ, Reynolds A, Piernas C, Schmidt JA, Papier
K, Carter JL, Key TJ, Perez-Cornago A. Associations between types and sources of
dietary carbohydrates and cardiovascular disease risk: a prospective cohort study of
UK Biobank participants. *BMC Med.* 2023;21:34. doi: 10.1186/s12916-022-02712-7

445 19. Woodward M. Rationale and tutorial for analysing and reporting sex

differences in cardiovascular associations. *Heart*. 2019;105:1701-1708. doi:

447 10.1136/heartjnl-2019-315299

448 20. Watling CZ, Schmidt JA, Dunneram Y, Tong TYN, Kelly RK, Knuppel A,

449 Travis RC, Key TJ, Perez-Cornago A. Risk of cancer in regular and low meat-eaters,

450 fish-eaters, and vegetarians: a prospective analysis of UK Biobank participants. *BMC*

451 *Med.* 2022;20:73. doi: 10.1186/s12916-022-02256-w

452 21. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, Abbott R,

453 Godwin J, Dyer A, Stamler J. Blood pressure, stroke, and coronary heart disease.

454 Part 1, Prolonged differences in blood pressure: prospective observational studies

455 corrected for the regression dilution bias. *Lancet.* 1990;335:765-774. doi:

456 10.1016/0140-6736(90)90878-9

457 22. Huang Y, Su L, Cai X, Mai W, Wang S, Hu Y, Wu Y, Tang H, Xu D.

458 Association of all-cause and cardiovascular mortality with prehypertension: a meta-

459 analysis. Am Heart J. 2014;167:160-168.e161. doi: 10.1016/j.ahj.2013.10.023

460 23. Huang Y, Wang S, Cai X, Mai W, Hu Y, Tang H, Xu D. Prehypertension and
461 incidence of cardiovascular disease: a meta-analysis. *BMC Med.* 2013;11:177. doi:
462 10.1186/1741-7015-11-177

463 24. Guo X, Zhang X, Guo L, Li Z, Zheng L, Yu S, Yang H, Zhou X, Zhang X, Sun

464 Z, et al. Association between pre-hypertension and cardiovascular outcomes: a

systematic review and meta-analysis of prospective studies. *Curr Hypertens Rep.*

466 2013;15:703-716. doi: 10.1007/s11906-013-0403-y

467 25. Nomura K, Asayama K, Thijs L, Niiranen TJ, Lujambio I, Boggia J, Hozawa A,

468 Ohkubo T, Hara A, Johansson JK, et al. Thresholds for conventional and home

469 blood pressure by sex and age in 5018 participants from 5 populations.

470 *Hypertension*. 2014;64:695-701. doi: 10.1161/hypertensionaha.114.03839

471 26. Tsimploulis A, Lam PH, Arundel C, Singh SN, Morgan CJ, Faselis C,

472 Deedwania P, Butler J, Aronow WS, Yancy CW, et al. Systolic blood pressure and

473 outcomes in patients with heart failure with preserved ejection fraction. JAMA

474 *Cardiol.* 2018;3:288-297. doi: 10.1001/jamacardio.2017.5365

475 27. Ravindrarajah R, Hazra NC, Hamada S, Charlton J, Jackson SHD, Dregan A,

476 Gulliford MC. Systolic blood pressure trajectory, frailty, and all-cause mortality >80

477 years of age: cohort study using electronic health records. *Circulation*.

478 2017;135:2357-2368. doi: 10.1161/circulationaha.116.026687

479 28. Millett ERC, Peters SAE, Woodward M. Sex differences in risk factors for

480 myocardial infarction: cohort study of UK Biobank participants. *BMJ*.

481 2018;363:k4247. doi: 10.1136/bmj.k4247

482	29. Anand SS, Islam S, Rosengren A, Franzosi MG, Steyn K, Yusufali AH, Keltai
483	M, Diaz R, Rangarajan S, Yusuf S. Risk factors for myocardial infarction in women
484	and men: insights from the INTERHEART study. Eur Heart J. 2008;29:932-940. doi:
485	10.1093/eurheartj/ehn018

- 486 30. Turnbull F, Woodward M, Neal B, Barzi F, Ninomiya T, Chalmers J, Perkovic
- 487 V, Li N, MacMahon S. Do men and women respond differently to blood pressure-
- 488 lowering treatment? Results of prospectively designed overviews of randomized
- 489 trials. *Eur Heart J.* 2008;29:2669-2680. doi: 10.1093/eurheartj/ehn427
- 490 31. Martins D, Nelson K, Pan D, Tareen N, Norris K. The effect of gender on age-
- 491 related blood pressure changes and the prevalence of isolated systolic hypertension

492 among older adults: data from NHANES III. J Gend Specif Med. 2001;4:10-13, 20.

- 493 32. Muntner P, Carey RM, Gidding S, Jones DW, Taler SJ, Wright JT, Jr.,
- 494 Whelton PK. Potential US population impact of the 2017 ACC/AHA high blood
- 495 pressure guideline. *Circulation*. 2018;137:109-118. doi:
- 496 10.1161/circulationaha.117.032582
- 497 33. Ji H, Kim A, Ebinger JE, Niiranen TJ, Claggett BL, Bairey Merz CN, Cheng S.

498 Sex differences in blood pressure trajectories over the life course. JAMA Cardiol.

- 499 2020;5:19-26. doi: 10.1001/jamacardio.2019.5306
- 500 34. Nwia SM, Leite APO, Li XC, Zhuo JL. Sex differences in the renin-
- 501 angiotensin-aldosterone system and its roles in hypertension, cardiovascular, and
- 502 kidney diseases. Front Cardiovasc Med. 2023;10:1198090. doi:
- 503 10.3389/fcvm.2023.1198090

- 504 35. Yanes LL, Romero DG, Iliescu R, Zhang H, Davis D, Reckelhoff JF.
- 505 Postmenopausal hypertension: role of the renin-angiotensin system. *Hypertension*.
- 506 2010;56:359-363. doi: 10.1161/hypertensionaha.110.152975
- 507 36. Vongpatanasin W. Autonomic regulation of blood pressure in menopause.

508 Semin Reprod Med. 2009;27:338-345. doi: 10.1055/s-0029-1225262

- 509 37. Majmudar NG, Robson SC, Ford GA. Effects of the menopause, gender, and
- 510 estrogen replacement therapy on vascular nitric oxide activity. J Clin Endocrinol

511 *Metab.* 2000;85:1577-1583. doi: 10.1210/jcem.85.4.6530

512 38. Remfry E, Ardissino M, McCracken C, Szabo L, Neubauer S, Harvey NC,

513 Mamas MA, Robson J, Petersen SE, Raisi-Estabragh Z. Sex-based differences in

risk factors for incident myocardial infarction and stroke in the UK Biobank. *Eur Heart*

515 J Qual Care Clin Outcomes. 2024;10:132-142. doi: 10.1093/ehjqcco/qcad029

516 39. Dickerson JA, Nagaraja HN, Raman SV. Gender-related differences in

517 coronary artery dimensions: a volumetric analysis. *Clin Cardiol*. 2010;33:E44-49. doi:

- 518 10.1002/clc.20509
- 519 40. Lønnebakken MT, Izzo R, Mancusi C, Losi MA, Stabile E, Rozza F, Gerdts E,

520 Trimarco B, de Luca N, de Simone G. Aortic root dimension and arterial stiffness in

521 arterial hypertension: the Campania Salute Network. J Hypertens. 2016;34:1109-

- 522 1114. doi: 10.1097/hjh.0000000000000932
- 523 41. Nguyen AH, Hurwitz M, Sullivan SA, Saad A, Kennedy JLW, Sharma G.

524 Update on sex specific risk factors in cardiovascular disease. *Front Cardiovasc Med.*

525 2024;11:1352675. doi: 10.3389/fcvm.2024.1352675

- 526 42. Beale AL, Meyer P, Marwick TH, Lam CSP, Kaye DM. Sex differences in
- 527 cardiovascular pathophysiology: why women are overrepresented in heart failure
- 528 with preserved ejection fraction. *Circulation*. 2018;138:198-205. doi:
- 529 10.1161/circulationaha.118.034271
- 530 43. Hondros CAB, Khan I, Solvik M, Hanseth S, Pedersen EKR, Hovland S,
- 531 Larsen TH, Lønnebakken MT. Compositional plaque progression in women and men
- 532 with non-obstructive coronary artery disease. Int J Cardiol Heart Vasc.
- 533 2024;51:101352. doi: 10.1016/j.ijcha.2024.101352
- 534 44. Yang ML, Xu C, Gupte T, Hoffmann TJ, Iribarren C, Zhou X, Ganesh SK. Sex-
- 535 specific genetic architecture of blood pressure. *Nat Med.* 2024;30:818-828. doi:
- 536 10.1038/s41591-024-02858-2
- Frost C , SG T. Correcting for regression dilution bias: comparison of methods
 for a single predictor variable. *J R Stat Soc: Ser A*. 2000;163:173–189.
- 539 46. Fry A, Littlejohns TJ, Sudlow C, Doherty N, Adamska L, Sprosen T, Collins R,
- 540 Allen NE. Comparison of sociodemographic and health-related characteristics of UK
- 541 Biobank participants with those of the general population. *Am J Epidemiol*.
- 542 2017;186:1026-1034. doi: 10.1093/aje/kwx246
- 543 47. Batty GD, Gale CR, Kivimäki M, Deary IJ, Bell S. Comparison of risk factor

studies associations in UK Biobank against representative, general population based studies

- 545 with conventional response rates: prospective cohort study and individual participant
- 546 meta-analysis. *BMJ*. 2020;368:m131. doi: 10.1136/bmj.m131
- 547 48. Karmali KN, Lloyd-Jones DM, van der Leeuw J, Goff DC, Jr., Yusuf S,
- 548 Zanchetti A, Glasziou P, Jackson R, Woodward M, Rodgers A, et al. Blood pressure-

- 549 lowering treatment strategies based on cardiovascular risk versus blood pressure: a
- 550 meta-analysis of individual participant data. *PLoS medicine*. 2018;15:e1002538. doi:
- 551 10.1371/journal.pmed.1002538
- 552 49. Nazarzadeh M, Canoy D, Bidel Z, Copland E, Rahimi K, Teo K, Davis BR,
- 553 Chalmers J, Pepine CJ, Woodward M. The Blood Pressure Lowering Treatment
- 554 Trialists' Collaboration: methodological clarifications of recent reports. *J Hypertens*.
- 555 2022;40:847-852. doi: 10.1097/hjh.000000000003107

Tables

	Overall	Women	Men
Characteristics	(n = 420,649)	(n = 235,556)	(n = 185,093)
Incident total CVD cases during follow-up, n	28,628	10,331	18,297
Incident CHD cases during follow-up	21,146	6,774	14,372
Incident stroke cases during follow-up	8,321	3,816	4,505
Age, mean (SD)	56.1 (8.1)	56.1 (8.0)	56.1 (8.2)
Ethnicity			
White	395,023 (94.4%)	221,497 (94.4%)	173,526 (94.3%)
Other*	23,587 (5.6%)	13,096 (5.6%)	10,491 (5.7%)

558 Table 1. Baseline characteristics and incident cardiovascular disease events for 420,649 UK Biobank participants.

Socioeconomic status

Townsend deprivation index score, median (IQR)	-2.2 (-3.7-0.4)	-2.2 (-3.6-0.4)	-2.2 (-3.7-0.5)
Townsend deprivation fifths:			
First (least deprived)	158,076 (37.6%)	88,349 (37.5%)	69,727 (37.7%)
Second	86,275 (20.5%)	48,820 (20.7%)	37,455 (20.2%)
Third	62,888 (15.0%)	35,753 (15.2%)	27,135 (14.7%)
Fourth	56,033 (13.3%)	31,621 (13.4%)	24,412 (13.2%)
Fifth (most deprived)	57,377 (13.6%)	31,013 (13.2%)	26,364 (14.2%)
Smoking status:			
Never	234,198 (56.0%)	141,014 (60.2%)	93,184 (50.6%)
Previous	141,099 (33.7%)	72,978 (31.1%)	68,121 (37.0%)
Current light (<15 cigarettes/day)	13,015 (3.1%)	7,698 (3.3%)	5,317 (2.9%)

Current medium (15-<30 cigarettes/day)	14,309 (3.4%)	7,061 (3.0%)	7,248 (3.9%)
Current heavy (>30 cigarettes/day)	15,966 (3.8%)	5,676 (2.4%)	10,290 (5.6%)
Diabetes	47,783 (11.4%)	24,742 (10.5%)	23,041 (12.5%)
Medication use:			
Antihypertensive medication use	95,299 (22.7%)	47,265 (20.1%)	48,034 (26.0%)
Lipid-lowering medication use	56,537 (13.4%)	24,759 (10.5%)	31,778 (17.2%)
Blood Pressure (mmHg):			
SBP, mean (SD)	137.7 (18.6)	135.1 (19.2)	141.0 (17.3)
DBP, mean (SD)	82.4 (10.1)	80.7 (9.9)	84.4 (9.9)
Hypertension	304,617 (72.4%)	155,855 (66.2%)	148,762 (80.4%)
BMI (kg/m ²):			
BMI, mean (SD)	27.3 (4.7)	26.9 (5.1)	27.7 (4.2)

Overweight (25-<30)	178,943 (42.5%)	86,903 (36.9%)	92,040 (49.7%)
Obesity (≥30)	98,752 (23.5%)	53,836 (22.9%)	44,916 (24.3%)
Serum lipids (mmol/L):			
Total cholesterol, mean (SD)	5.8 (1.1)	5.9 (1.1)	5.6 (1.1)
HDL-C, mean (SD)	1.5 (0.4)	1.6 (0.4)	1.3 (0.3)

Numbers are participant numbers (%), with % representing the column percentage estimated excluding participants with missing responses, unless otherwise specified.

*Includes Asian or Asian British, black or black British, Caribbean, African, any other black background, Chinese, other ethnic group, white and black Caribbean, white and black African, white and Asian, any other mixed background, Indian, Pakistani, Bangladeshi, any other Asian background.

BMI = body mass index; CHD = coronary heart disease; CVD = cardiovascular disease; DBP = diastolic blood pressure; HDL-C = high-density lipoprotein cholesterol; IQR = interquartile range; kg/m^2 = kilogram per square meter; mmHg = millimeters of mercury; mmol/L = millimoles per liter; SBP = systolic blood pressure; SD = standard deviation.

medRxiv preprint doi: https://doi.org/10.1101/2024.09.03.24313046; this version posted September 4, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY 4.0 International license .



Figures and Figure Legends 560

Figure 1. Risks of cardiovascular disease by level of blood pressure for each 562 sex. Scatterplot showing age-adjusted risks (per 10,000 person-years) for incident 563 564 cardiovascular disease across categories of (A) SBP and (B) DBP in women (red) and men (blue). Vertical lines indicate corresponding 95% confidence intervals. DBP 565 = diastolic blood pressure; mmHg = millimeters of mercury; SBP = systolic blood 566 567 pressure.

medRxiv preprint doi: https://doi.org/10.1101/2024.09.03.24313046; this version posted September 4, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .





Figure 2. Sex-specific relative risks relating blood pressure to cardiovascular 569 570 disease. Scatterplot showing age-adjusted sex-specific relative risks for incident 571 cardiovascular disease across categories of (A) SBP and (B) DBP in women (red) and men (blue). Vertical lines indicate corresponding 95% confidence intervals. The 572 573 reference category for SBP was 110-115 mmHg in both sexes separately. The reference category for DBP was 70-<75 mmHg in both sexes separately. DBP = 574 diastolic blood pressure; mmHg = millimeters of mercury; SBP = systolic blood 575 576 pressure.

medRxiv preprint doi: https://doi.org/10.1101/2024.09.03.24313046; this version posted September 4, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in





577



cardiovascular disease. Scatterplot showing age-adjusted sex-specific relative 579 risks for incident cardiovascular disease across categories of (A) SBP and (B) DBP 580 581 in women (red) and men (blue). Vertical lines indicate corresponding 95% confidence intervals. The reference category for SBP was men at 110-115 mmHg for 582 583 both women and men. The reference category for DBP was men at 70-<75 mmHg for both women and men. DBP = diastolic blood pressure; mmHg = millimeters of 584 mercury; SBP = systolic blood pressure. 585



586

587 Figure 4. Sex-specific relative risks relating blood pressure level to cardiovascular disease by sex and age group. Forest

588 plots showing sex and age-specific RRs relating continuous blood pressure and hypertension status to incident cardiovascular

- 589 disease in women (red) and men (blue). Horizontal lines indicate corresponding 95% confidence intervals. CI = confidence interval;
- 590 DBP = diastolic blood pressure; mmHg = millimeters of mercury; SBP = systolic blood pressure; RR = relative risk.



592 Figure 5. Sex-specific risk differences and relative risks relating systolic blood 593 pressure to incident cardiovascular disease. Line graph showing age-adjusted 594 sex-specific RDs per 10,000 person-years (dashed lines) and RRs (solid lines) for 595 incident cardiovascular disease across categories of SBP in women (red) and men 596 (blue). The reference category for SBP was 110-115 mmHg in both sexes 597 separately. DBP = diastolic blood pressure; mmHg = millimeters of mercury; RD = risk difference; RR = relative risk; SBP = systolic blood pressure. 598